VANCOUVER, BC, June 17, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“ MYND“) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce a Letter of Intent (“LOI”) with Eyam Vaccines and Immunotherapeutics (“Eyam“). The LOI outlines an Exclusive Licensing Agreement with respect to Eyam’s proprietary…


Previous articleMINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
Next articleRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics